Mary E Garner

Title: Mary E Garner: Innovator in Targeted Drug Delivery

Introduction

Mary E Garner is a prominent inventor based in Oakland, CA (US). She has made significant contributions to the field of targeted drug delivery, holding 2 patents that showcase her innovative approach to medical technology.

Latest Patents

Her latest patents include the development of aptamer conjugates with N-heterocyclic carbene metal complexes for targeted drug delivery. These conjugates consist of an aptamer coupled through a hydrolytically stable bond to an N-heterocyclic-carbene metal complex (NHCM) or a bis-N-heterocyclic-carbene metal complex (bis-NHCM). The aptamer-NHCM conjugate is designed to selectively bind to specific cell receptors, allowing for the targeted delivery of cytotoxic NHCM to cells responsible for diseases such as cancer. The preparation method involves installing a coupling group to the metal complex that can bond with a functional group on the aptamer, ensuring stability in the absence of conditions that promote bond cleavage.

Career Highlights

Mary E Garner is affiliated with the University of Florida Research Foundation, Incorporated, where she continues to advance her research in drug delivery systems. Her work is characterized by a commitment to improving therapeutic outcomes through innovative technologies.

Collaborations

Some of her notable coworkers include Adam Steven Veige and Weijia Niu, who contribute to her research endeavors and collaborative projects.

Conclusion

Mary E Garner's contributions to the field of targeted drug delivery exemplify her dedication to innovation in medical technology. Her patents reflect a significant advancement in the ability to direct treatments to specific cells, potentially transforming cancer therapy.